NCT04446793 2024-02-12
Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer
Cardiff Oncology
No longer available
Cardiff Oncology
Tracon Pharmaceuticals Inc.